A mass spectrometry-based plasma protein panel targeting the tumor microenvironment in patients with breast cancer

Journal of Proteomics

Volumn 81, Issue , 2013, Pages 135-147

  Cohen, Alejandro ^a   Wang, Edwin ^a   Chisholm, Kenneth A ^a   Kostyleva, Ripsik ^a   O'Connor McCourt, Maureen ^a   Pinto, Devanand M ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Breast cancer; Intraprotein variability; Plasma proteomics; Tumor microenvironment

Indexed keywords

ALPHA 1 MICROGLOBULIN; CLUSTERIN; FIBRONECTIN; GELSOLIN; INTER ALPHA TRYPSIN INHIBITOR;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; ENZYME DEGRADATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN METHYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEOMICS; TISSUE LEVEL; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT;

BREAST NEOPLASMS; CARCINOMA, DUCTAL; CELL LINE, TUMOR; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MICROENVIRONMENT;

EID: 84877837880     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.11.004     Document Type: Article

References (76)

1. Burstein H.L., Harris L.N., Marcom P.K., Lambert-Falls R., Havlin K., Overmoyer B., et al. Trastuzumab and vinorelbine as first-line therapy for her2-overexpressing metastatic breast cancer: multicenter phase ii trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003, 21:2889-2895.
2. Ross J.S., Fletcher J.A. The her-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16:413-428.
3. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
4. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (er)-negative, progesterone receptor (pr)-negative, and her2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 2007, 109:1721-1728.
5. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
6. Vlahou A., Laronga C., Wilson L., Gregory B., Fournier K., McGaughey D., et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003, 4:203-209.
7. Le Naour F., Misek D.E., Krause M.C., Deneux L., Giordano T.J., Scholl S., et al. Proteomics-based identification of rs/dj-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001, 7:3328-3335.
8. Huang H.L., Stasyk T., Morandell S., Dieplinger H., Falkensammer G., Griesmacher A., et al. Biomarker discovery in breast cancer serum using 2-d differential gel electrophoresis/maldi-tof/tof and data validation by routine clinical assays. Electrophoresis 2006, 27:1641-1650.
9. Kang U.B., Ahn Y., Lee J.W., Kim Y.H., Kim J., Yu M.H., et al. Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker. BMC Cancer 2010, 10.
10. Hamrita B., Nasr H.B., Chahed K., Kabbage M., Chouchane L. Proteomic analysis of human breast cancer: new technologies and clinical applications for biomarker profiling. J Proteomics Bioinform 2010, 3:91-98.
11. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
12. Hill J.J., Tremblay T.L., Pen A., Li J., Robotham A.C., Lenferink A.E., et al. Identification of vascular breast tumor markers by laser capture microdissection and label-free LC-MS. J Proteome Res 2011, 10:2479-2493.
13. Li J., LA, Deng Y., Collins C., Cui Q., Purisima E.O., et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun 2010, 1.
14. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
15. Ben-Baruch A. Host microenvironment in breast cancer development. Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003, 5:31-36.
16. Amon L.M., Pitteri S.J., Li C.I., McIntosh M., Ladd J.J., Disis M., et al. Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. Cancer Res 2012, 72:1935-1942. 10.1158/0008-5472.CAN-11-3266.
17. Tom R., Bisson L., Durocher Y. Transfection of HEK293-EBNA1 cells in suspension with linear PEI for production of recombinant proteins. Cold Spring Harb Protoc 2008, 3.
18. Tom R., Bisson L., Durocher Y. Purification of his-tagged proteins using fractogel-cobalt. Cold Spring Harb Protoc 2008, 3.
19. Edge S.B., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC cancer staging manual 2010, Springer.
20. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., et al. TM4 microarray software suite. Methods Enzymol 2006, 11:134-193.
21. Saeed A.I., Sharov V., White J., Li J., Liang W., Bhagabati N., et al. Tm4: a free, open-source system for microarray data management and analysis. Biotechniques 2003, 34:374-378.
22. Craig R., Cortens J.P., Beavis R.C. The use of proteotypic peptide libraries for protein identification. Rapid Commun Mass Spectrom 2005, 19:1844-1850.
23. Huberty C.J. Applied discriminant analysis 1994, Jon Wiley and Sons, New York.
24. Ghosh D., Chinnaiyan A.M. Classification and selection of biomarkers in genomic data using LASSO. J Biomed Biotechnol 2005, 2:147-154.
25. Ambesi A., Klein R.M., Pumiglia K.M., McKeown-Longo P.J. Anastellin, a fragment of the first type III repeat of fibronectin, inhibits extracellular signal-regulated kinase and causes G1 arrest in human microvessel endothelial cells. Cancer Res 2005, 65:148-156.
26. Morla A., Zhang Z., Ruoslahti E. Superfibronectin is a functionally distinct form of fibronectin. Nature 1994, 367:193-196.
27. Yi M., Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci 2001, 98:620-624.
28. You R., Matthew K.R., Zheng Mingzhe, McKeown-Longo P.J. Regulation of p38 MAP kinase by anastellin is independent of anastellin's effect on matrix fibronectin. Matrix Biol 2009, 28:101-109.
29. Choate J.J., Mosher D.F. Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia. Cancer 1983, 51:1142-1147.
30. Ruelland A., Kerbrat P., Clerc C., Legras B., Cloarec L. Level of plasma fibronectin in patients with breast cancer, level of plasma fibronectin in patients with breast cancer. Clin Chim Acta 1998, 178:283-288.
31. Süer S., Baloglu H., Güngör Z., Sönmez H., Kökoglu E. The distribution of tissue fibronectin and sialic acid in human breast cancer. Cancer Biochem Biophys 1998, 16:63-70.
32. Labat-Robert J., Birembaut P., Adnet J.J., Mercantini F., Robert L. Loss of fibronectin in human breast cancer. Cell Biol Int Rep 1980, 4:609-616.
33. Bal de Kier Joffe P.L., Mariotto R., Eijan A.M., de Lustig E.S. Fibronectin and laminin expression in breast cancer and lymph node metastases. Lack of correlation with fibronectin plasmatic levels. Medicina 1988, 48:499-505.
34. Guarneri D., Zanardi S., Boccardo F., Castellani P., Balza E., Borsi L., et al. Fibronectin concentration in plasma of patients with breast cancer. Ann N Y Acad Sci 1986, 464.
35. Christensen L. The distribution of fibronectin, laminin and tetranectin in human breast cancer with special attention to the extracellular matrix. APMIS Suppl 1992, 100:1-39.
36. Hayashido Y., Lucas A., Rougeot C., Godyna S., Argraves W.S., Rochefort H. Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin. Int J Cancer 1998, 75:654-658.
37. Jia Y., Zheng Z.Z., Markwart S.M., Rockwood K.F., Woods Ignatoski K.M., Ethier S.P., et al. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res 2004, 64:8674-8681.
38. McCaig C., Perks C., Holly J. Intrinsic actions of igfbp-3 and igfbp-5 on hs578t breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 2002, 115:4293-4303.
39. Xing H., Cao Y., Weng D., Tao W., Song X., Wang W., et al. Fibronectin-mediated activation of akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis 2008, 13:213-223.
40. Cheng H.C., Abdel-Ghany M., Elble R.C., Pauli B.U. Lung endothelial dipeptidyl peptidase iv promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem 1998, 273:24207-24215.
41. Ioachim E., Charchanti A., Briasoulis E., Karavasilis V., Tsanou H., Arvanitis D.L., et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type iv and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38:2362-2370.
42. Ruiz-Garcia E., Scott V., MacHavoine C., Bidart J.M., Lacroix L., Delaloge S., et al. Gene expression profiling identifies fibronectin 1 and cxcl9 as candidate biomarkers for breast cancer screening. Br J Cancer 2010, 102:462-468.
43. Kaspar M., Zardi L., Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006, 118:1331-1339.
44. Schulz D.M., Bollner C., Thomas G., Atkinson M., Esposito I., Hofler H., et al. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 2009, 8:3430-3438.
45. July L.V., Akbari M., Zellweger T., Jones E.C., Goldenberg S.L., Gleave M.E. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002, 50:179-188.
46. Saverio B., Pierpaola D., Serenella A., Cesare C., Bruno M., Auro T., et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000, 60:28-34.
47. Scaltriti M., Brausi M., Amorosi A., Caporali A., D'Arca D., Astancolle S., et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004, 108:23-30.
48. Steinberg J., Oyasu R., Lang S., Sintich S., Rademaker A., Lee C., et al. Intracellular levels of sgp-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997, 3:1707-1711.
49. Xie M.J., Motoo Y., Su S.B., Mouri H., Ohtsubo K., Matsubara F., et al. Expression of clusterin in human pancreatic cancer. Pancreas 2002, 25:234-238.
50. Yang G., Li X., Xie D. Clusterin protein expression and apoptosis in ovarian cancer. Chin J Clin Oncol 2007, 34:14-16.
51. Yang G.F., Li X., Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009, 19:1342-1346.
52. Andersen C.L., Schepeler T., Thorsen K., Birkenkamp-Demtroder K., Mansilla F., Aaltonen L.A., et al. Clusterin expression in normal mucosa and colorectal cancer. Mol Cell Proteomics 2007, 6:1039-1048.
53. Rodríguez-Piñeiro A.M., de la Cadena M.P., López-Saco A., Rodriguez-Berrocal F.J. Differential expression of serum clusterin isoforms in colorectal cancer, Molecular and Cellular. Proteomics 2006, 5:1647-1657.
54. Poon S., Easterbrook-Smith S.B., Rybchyn M.S., Carver J.A., Wilson M.R. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 2000, 39:15953-15960.
55. Ranney M.K., Ahmed I.S.A., Potts K.R., Craven R.J. Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer. Biochim Biophys Acta Mol Basis Dis 2007, 1772:1103-1111.
56. Rizzi F., Caccamo A., Belloni L., Bettuzzi S. Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol 2009, 219:314-323.
57. Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.-Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005, 7:909-915.
58. Trougakos I.P., So A., Jansen B., Gleave M.E., Gonos E.S. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004, 64:1834-1842.
59. Zhang S., Zhang D., Zhu Y., Guo H., Zhao X., Sun B. Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol Cancer Res Treat 2006, 5:573-578.
60. Krüger S., Ola V., Fischer D., Feller A.C., Friedrich M. Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma 2007, 54:46-50.
61. Yom C.K., WH, Min S.Y., Kang S.Y., Kim H.S. Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res 2009, 29:3909-3912.
62. Sun B., Zhang S., Zhang D., Liu Y., Li Y., Rong Z., et al. Clusterin is associated with spontaneous breast cancer in ta2 mice. FEBS Lett 2007, 581:3277-3282.
63. Flanagan L., Whyte L., Chatterjee N., Tenniswood M. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer 2010, 10.
64. Haga K. The mechanism for reduced expression of gelsolin, tumor suppressor protein, in bladder cancer. Hokkaido Igaku Zasshi 2003, 78:29-37.
65. Sanchez-Carbayo M., Socci N., Richstone L., Corton M., Behrendt N., Wulkfuhle J., et al. Genomic and proteomic profiles reveal the association of gelsolin to tp53 status and bladder cancer progression. Am J Pathol 2007, 171:1650-1658.
66. Tanaka M., Mullauer L., Ogiso Y., Fujita H., Moriya S., Furuuchi K., et al. Gelsolin: A candidate for suppressor of human bladder cancer. Cancer Res 1995, 55:3228-3232.
67. Dosaka-Akita H., Hommura F., Fujita H., Kinoshita I., Nishi M., Morikawa T., et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 1998, 58:322-327.
68. Yang J., Ramnath N., Moysich K.B., Asch H.L., Swede H., Alrawi S.J., et al. Prognostic significance of mcm2, ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer 2006.
69. Yang J., Tan D., Asch H.L., Swede H., Bepler G., Geradts J., et al. Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. Lung Cancer 2004, 46:29-42.
70. Dong Y., Asch H., Medina D., Ip C., Ip M., Guzman R., et al. Concurrent deregulation of gelsolin and cyclin d1 in the majority of human and rodent breast cancers. Int J Cancer 1999, 81:930-938.
71. Dong Y., Asch H., Ying A., Asch B.B. Molecular mechanism of transcriptional repression of gelsolin in human breast cancer cells. Exp Cell Res 2002, 276:328-336.
72. Kim J., Lee J.E., Heynen-Genel S., Suyama E., Ono K., Lee K., et al. Functional genomic screen for modulators of ciliogenesis and cilium length. Nature 2010, 464:1048-1051.
73. Lind S.E., Janmey P.A. Human plasma gelsolin binds to fibronectin. J Biol Chem 1984, 259:13262-13266.
74. Asch H.L., Head K., Dong Y., Natoli F., Winston J.S., Connolly J.L., et al. Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 1996, 56:4841-4845.
75. Liu J., Liu Y.G., Huang R., Yao C., Li S., Yang W., et al. Concurrent down-regulation of egr-1 and gelsolin in the majority of human breast cancer cells. Cancer Genomics Proteomics 2007, 4:377-386.
76. Jensen L.J., Kuhn M., Stark M., Chaffron S., Creevey C., Muller J., et al. STRING - a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009, 37:D412-D416.